It was a very pleasant and positive experiece meeting Dr. Reeves today, he is very down to earth, easy to talk to and after about 15 minutes, you realize your talking to a real genious. He has a real passion for the FWS and had shown me some of the most recent positive findings, he was pretty excited about something to do with the clear detection of Phase Metabolic Change. I'm not really boned up on the First Warning System yet, but having the master explain it to me, showing how the test result detected the abnormality, and pointing out on a mamogram, where the problem was. He made it clear that there is no other technology in existance that can do what the FWS can do.

Dr. William Reeves office is in Pompano Beach, FL. I met his son Jonathon Reeves, VP of operations as well, a scientist/inventor as well, they are very decent people who appear to have a serious passion for science. BFW advertising people were in the next room as well as a new web-site guy, one month from now the web-site should have a serious face-lift, three different videos are being made now on the mastascope, for the web-site.

Dr. Reeves brought out a wooden box containing the MastaScope, showed me how it all hooked up and compared how compact and easy to manage it is to Acueity's large bulky system, also compared the disposable part of Acueity's scope to Lifelines, Acueity's disposable part needs to be replaced after 3-4 procedures, Lifelines needs replacement after 30 procedures, and how the MastaScope has a much higher resolution then Acueity.

We talked about the MastaScope for a while, I think he enjoyed the fact that some guy outa nowhere knew so much about his creation, I told him my sister got into this stock after I explained how it finds the problem before its too late and how she wanted an IDE(Intraductal Endoscopy), the new procedure the MastaScope will be used for. I told him she loved the idea that there is something that can detect abnormalitys up to 10 years before cancer ever has a chance to develop, and she owns 400,000 shares to boot. His heart and soul is into what he does, he said he can't really let the market makers get to him too much because he has so much going on and must be able to concentrate on the big picture, plus so much is going to happen soon that the NSS are gonna get blown outa the water. One interesting note, we were talking about that airline shipping co. that successfully sued their naked short mm's, Dr. Reeves told me, an MM called him once and said if you ever pull any crap on us we will pull you down, the way they pulled that company down.

The MastaScope is manufactured in New England, Lifeline has an arrangement with a company, Reeves said he can't really say too much about this except it has something to do with a big optic firm and Nasa. Said its not really worth it to own your own factory, and this present situation is working out very well. The scopes, Blades, and screws are stored on the 2nd floor of the building I was in, he commented on how a huge shipment just went out. I said, "right, the Egypt order!", he said no, something completley different.

The gross margin made on the screws and blades is 40%, I was given new lititure on the screws,scope,ect, I will scan them and get them in the e-mail circuit unless sharpguy can put them on the LBTT spot. I also took digital piks, of the office, Dr. Reeves, Jonathan Reeves, CE Mark cert,ect.

I asked about the Audit and getting off the pinks, I think Mr. Holmes is the money guy and Dr. Reeves is the scientist, but its something he wants as much as everyone else.

Some big things are going to be coming out of the Clevland clinic soon. I'm racking my brain like crazy, trying to remember the conversation.

Reeves had brought up some guy named, Pedro Escovar a few times, he is a new heavy weight that was just brought aboard. I'm not 100% sure but think he is another physician/consultant.

Dr. Reeves had shown me his latest article for the periodicle, Breast Cancer Review, published by Asrazeneca Oncology, its not published yet but maybe it can be found online in a week or two. He had written something monumental about alpha phetal proteins and early detection of cancer, it was facinating but I just can't remember the details, bottom line, this guy is inventing stuff that nobody else has ever thought of before, he is the real deal, as is the company, I was extremley impressed by this man, and feel he is up to the task.

He sounded very positive about funding, said a PR won't be too far off.

As far as the Naked shorting MM's, he is a very dignified human being, I think its tough on him to have this crimminal element be such a big part of his accomplishments. He said it was like 80 million dollars, that have been stolen, then he pointed to me and said its u and other investors who they stole it from! I told him, "yea, no kidding, and I don't want to take it anymore" They are doing things they can't talk about but he gave me some new lititure that I haven't read yet from Breslin Associates,P.A. and said Breslin is the man to talk to about taking action against the MM's, who constantly steal from all of us. When he introduced me to his son, he said heres the guy whose gonna rally the troops against the MM's, hehe, I liked that!

Overheard them talking about Carlo, apparently he is working in over-drive, and don't forget about Frank, PR's to follow. They are selling a lot of these scopes, and Reeves said 150 leads, that came from the European conf. are all interested, said the booth was very busy with very impressed buyers.

It was close to 5 m, memorial weekend upon us, so I picked a good laid back time, they were swmaped up till 3 m. Before I left Dr. Reeves and his son were showing me things that nobody knows about, I told them both, " you realize you guys are a lot better then the way you make yourselves appear!" They agreed.

I got to reload all my software on my recently crashed computer, I'll have the pictures and scans of the new lititure done later on.

These God Dammmed MM's shook a lot of peoples confidence, but its just the smart move to buy as much as u can, and hold on to it.

(Voluntary Disclosure: Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy)

NASHUA, N.H.--(BUSINESS WIRE)--June 2, 2004--iCAD, Inc. (Nasdaq:ICAD - News), which designs, develops and markets Computer Aided Detection (CAD) imaging technology and systems for the early detection of breast cancer and other medical applications announced approval from the United States Food and Drug Administration (FDA) for release of iCAD's new Second Look® 200 system for early detection of breast cancer with substantially improved cancer detection software. The new combination of Second Look 200 with iCAD's Version 6.0 cancer detection software represents both the most sensitive cancer detection solution available, and the least expensive.

The Second Look 200 is specifically designed to make CAD accessible to smaller Breast Care Centers. It can easily analyze up to 15 cases per day, is fully automated, fits on a counter top and is priced below $70,000. Version 6.0 detection software offers up to 94% sensitivity to all breast cancers. Orders for the Second Look 200 are now being accepted by iCAD resellers. iCAD has indicated the Second Look 200 system will also be made available on a fee-per-procedure basis the company calls "ClickCAD(TM)".

"The vast majority of CAD systems in use today have been installed in hospitals, women's health centers and mammography clinics that perform twenty or more procedures per day," noted W. Scott Parr, Chief Executive Officer of iCAD, Inc. "We believe our Second Look 200 solution is a category-defining CAD system, in the sense that it is the first product on the market that will allow lower-volume clinics to provide CAD services to women on a cost-effective basis. The Second Look 200 is simple to operate and self-training in nature, has been designed to fit within the limited space requirements of smaller mammography clinics, and will be priced well below currently available CAD systems.

"We believe the Second Look 200 system will appeal to the thousands of low volume mammography clinics that cannot afford CAD systems currently on the market," continued Parr. "With the Second Look 200 system, we envision a significant expansion in market opportunity for our company within the emerging medical market for computer aided detection. Most importantly, this product will make the benefits of earlier computer aided detection of breast cancer affordable and accessible to an increasing number of women at risk."

About iCAD, Inc.

iCAD develops, engineers, manufactures and markets computer aided detection (CAD) products for the early detection of breast cancer and other health-care related applications. Early detection of breast cancer can save lives and often permits less costly, less invasive and less disfiguring cancer treatment options than when the cancer is detected at a later stage. Computer-aided detection from iCAD can detect 23% of breast cancers, an average of 15 months earlier than screening mammography alone.

iCAD is the only independent, integrated digitizer hardware and CAD software company offering computer aided detection solutions. As such, iCAD is able to reduce costs at each step in the CAD product design, production and assembly process. The Company believes its vertical integration of CAD and hardware development results in better integration of software and film digitizer components, lower production costs and reduced administrative overhead. These achievements have allowed iCAD to progressively enhance its CAD product line, while reducing the costs of CAD to many customers and allowing more women to realize the benefits inherent in the early detection of breast cancer.

On December 31, 2003, iCAD merged with and acquired CADx Systems, Inc. and its parent company Qualia Computing, Inc., bringing together two of the three companies approved by the US Food and Drug Administration (FDA) to market computer aided (CAD) systems for the detection of breast cancer in the United States. The Company is headquartered in Nashua, New Hampshire and its common stock is listed on The Nasdaq Stock Market under the symbol "ICAD". More information on iCAD's products can be found at www.icadmed.com.

Business Editors

RENO, Nev.--(BUSINESS WIRE)--LBTT--
Jim Holmes, CEO Lifeline Biotechnologies Inc. (OTC:
LBTT) announced that the certified public accounting firm of Malone &
Bailey, PLLC, Houston, which was retained earlier this year, is in the
process of conducting the company's financial audit as of Dec. 31,
2003.
Holmes stated that, "Lifeline expects, once the audit has been
completed, to proceed with the appropriate SEC filings to register the
company and to comply with the requirements for listing on the OTC
Bulletin Board. With the sale of products finally started, we're
pleased that Lifeline has advanced from the 'Development Stage Entity'
classification. This move from a Development Stage Entity makes the
audit much simpler and the audit report less complicated."
Malone & Bailey specializes in providing high-integrity compliance
services to small publicly traded companies. Holmes noted, "I'm
pleased to be working with Malone & Bailey, particularly the
experience they bring dealing with small public companies."
Dr. William Reeves, founder and president of Lifeline,
acknowledged that, "The company, while continually frustrated with the
seeming manipulation of its shares on the Pink Sheets, made the
difficult decision, in previous years, to abandon the audit and plans
for listing on the OTC Bulletin Board in order to commit resources to
product development and marketing. Now, the company is at a stage
where we are producing increasing revenues."
Holmes went on to note that, "Pursuing a move off the Pinks is a
priority. This move to the OTC Bulletin Board will allow shareholders
to monitor the progress of the company and should broaden our investor
base for those that would not invest in a non-reporting company."

Lifeline's Web site address: www.lbti.com

This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. In
particular, when used in the preceding discussion, the words
"believe," "expects," "projects," "forecasts," "intends," "will,"
"anticipated," or "may," and similar conditional expressions are
intended to identify forward-looking statements within the meaning of
the Act and subject to the safe harbor created by the Act. All
forward-looking statements may involve risks and uncertainties.

KEYWORD: NEVADA
INDUSTRY KEYWORD: BANKING BIOTECHNOLOGY
SOURCE: Lifeline Biotechnologies Inc.

CONTACT INFORMATION:
Lifeline Biotechnologies, Reno
Jim Holmes, 775-324-1933
jholmes@lbti.com
or
Stock Enterprises
Jim Stock, 866-242-2405 (Investor Relations)
stockenter@aol.com

------------------
Due Da Due......But Be Quick About It!!!!!